1. We first propose that in advanced TC, not only tumor-associated macrophages (TAMs), but also circulating monocytes and bone marrow (BM) myeloid progenitors are functionally reprogrammed by tumor-derived metabolites even before their recruitment…
ID
Bron
Aandoening
Thyroid carcinoma
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Transcriptional and epigenetic signature and function of TAMs, BM myeloid progenitors and circulating macrophages before and after treatment.
Doel van het onderzoek
1. We first propose that in advanced TC, not only tumor-associated macrophages (TAMs), but also circulating monocytes and bone marrow (BM) myeloid progenitors are functionally reprogrammed by tumor-derived metabolites even before their recruitment in the TME.
2. Radioactive iodide (I131)(RAI) is a very effective therapy for patients with TC, but is less effective in patients with advanced, metastatic tumors. We hypothesize that by exposing tumor antigens to the immune system, RAI might induce immunogenic effects at the level of the TME with reprogramming of both TAMs present in the TME and circulating monocytes, towards a tumor suppressive phenotype. This may further potentiate the effects of RAI. In addition this could be explored in the future as a basis for immunotherapy for tumors that are refractory to conventional treatment.
Onderzoeksopzet
-before treatment
-surgery
-30 days after surgery
-7days after RAI treatment
-30days after RAI treatment
Onderzoeksproduct en/of interventie
Not applicable.
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
In general: Subjects should be at least 18 years old and mentally competent
Patients with TC:
Group 1:
-newly diagnosed patients with TC that are therapy naïve and are planned to receive conventional treatment by surgery followed by RAI
-no evidence of local or distant metastases
Group 2:
-patients with TC with evidence of distant metastases (either newly diagnosed patients who are therapy naïve or patients with persistent or recurrent disease)
-at least 4 months since the previous treatment with RAI (in the patients who have had this treatment in the past)
Controls:
Group 3:
-patients with MNG that are euthyroid and in which the decision has been taken to undergo surgery because of obstructive symptoms or for cosmetic reasons
Group 4:
-patients with MNG that are euthyroid and in which the decision has been taken to undergo RAI because of obstructive symptoms.
Group 5:
-healthy individuals who are euthyroid and have no evidence of thyroid disease.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
A potential subject who meets any of the following criteria will be excluded from participation in this study:
-Mentally incompetent
-Pregnant or breastfeeding
-Known inflammatory or infectious diseases or an immunosuppressive status;
-Using medication interfering with the immune system
-Reduced platelets counts or other conditions associated with an increased risk of bleeding
-Severe comorbidities: other active malignancy (except for basal cell carcinoma)
-Serious psychiatric pathology
-A self-reported alcohol consumption of >21 units per week
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL6817 |
| NTR-old | NTR7003 |
| Ander register | NL62671.091.17 : 2017-3628 |